Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):321-6. doi: 10.3928/23258160-20150323-04.


Background and objective: To examine the macula in preterm infants treated with bevacizumab (Avastin; Genentech, South San Francisco, CA) for retinopathy of prematurity (ROP) using spectral domain optical coherence tomography (SD-OCT).

Patients and methods: Twenty eyes (of 11 patients) treated with Avastin only or in addition to photocoagulation and vitreous surgery were included. Imaging was performed with a portable spectral-domain optical coherence tomography (OCT) device. Macular measurements, including the foveal and parafoveal index were calculated. RetCam (Clarity Medical Systems, Pleasanton, CA) photographs were obtained for all patients.

Results: Mean age of patients at OCT examination was 28.9 months (range: 4 to 50 months). Thirteen eyes (65%) developed foveal contour (FC), and seven eyes (35%) did not. Earlier gestational age and zone I disease were associated with absence of FC development. In patients without FC, two of the five eyes had vision better than 20/400, compared with 10 of 11 eyes with FC.

Conclusion: Vision tends to be better in Avastin-treated eyes when an FC is present. Morphological characteristics of retinal anatomy may predict visual function.

MeSH terms

  • Adolescent
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Laser Coagulation
  • Macula Lutea / pathology*
  • Male
  • Retinopathy of Prematurity / drug therapy*
  • Retinopathy of Prematurity / physiopathology
  • Retinopathy of Prematurity / surgery
  • Tomography, Optical Coherence*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab